Welcome to the UK STERLING PMR trial website. If you live in Australia, then please follow the link below for more relevant trial information.
If you are a patient or are reading this on behalf of someone you know then please refer to the Patients and Participants section to find out who is eligible to join the STERLING- PMR study.
The Leeds institute of Clinical Studies based at the University of Leeds is helping to deliver STERLING- PMR, a new international clinical trial funded by the Health Technology Assessment (HTA) Programme to investigate how to improve outcomes for patients with relapsing Polymyalgia rheumatica (PMR) in both secondary and primary care with the use of disease-modifying anti-rheumatic drugs (DMARDs).
STERLING-PMR stands for: STEroid-Reducing Options for ReLapsING PMR. It’s aim is to compare the clinical and cost-effectiveness of adding DMARDs to steroid-tapering treatment for patients with relapsing PMR, versus steroid-tapering alone.
A summary of how this trial is going to be run can be found in the protocol summary [Link to Protocol Summary].
For more information on DMARDS please follow the link below for the British Society for Rheumatology (BSR)
[BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs]